Login to Your Account

Pharma: Clinic Roundup

Thursday, July 12, 2012
• Eli Lilly and Co., of Indianapolis, reported negative results from study H8Y-MC-HBBM investigating pomaglumetad methionil, also known as mGlu2/3, in patients with acute exacerbations of schizophrenia.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription